Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

How accurate are stock forecasts?

Stock forecasts are based on technical and fundamental analysis but should not be considered as guaranteed predictions. Past performance does not guarantee future results.

How do I analyze ARQT stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate ARQT investment potential.

What is ARQT stock price today?

Get real-time ARQT stock price, historical data, and price charts on Financhill. Track ARQT performance with our advanced analysis tools.

Is ARQT a good investment?

Evaluate ARQT investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy ARQT stock?

To buy ARQT stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of ARQT?

View detailed market capitalization data and company valuation metrics for ARQT on our comprehensive analysis page.

What is the P/E ratio of ARQT?

Use our fundamental analysis tools to view ARQT P/E ratio and compare valuation metrics with industry peers.

What are ARQT earnings?

View ARQT earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Arcutis Biotherapeutics, Inc. Stock Predictions

Still Time to Get In: RAD Intel at $0.85/Share

DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi

Buy

ARQT
Arcutis Biotherapeutics, Inc.

Last Price:

$31.19

Seasonality Move:

97.78%

7 Day Trial

ALL ACCESS PASS

$ 7

AI Powerhouse Raises Price - But Room Remains

Arcutis Biotherapeutics, Inc. Stock Forecast

Over the next 52 weeks, Arcutis Biotherapeutics, Inc. has on average historically risen by 110% based on the past 5 years of stock performance.
Arcutis Biotherapeutics, Inc. has risen higher in 3 of those 5 years over the subsequent 52-week period, corresponding to a historical accuracy of 60%
Is Arcutis Biotherapeutics, Inc. Stock Undervalued?

The current Arcutis Biotherapeutics, Inc. [ARQT] share price is $29.96. The Score for ARQT is 90, which is 80% above its historic median score of 50, and infers lower risk than normal.
ARQT is currently trading in the 80-90% percentile range relative to its historical Stock Score levels.

Will Arcutis Biotherapeutics, Inc. Stock Go Up Next Year?

Over the next 52 weeks, Arcutis Biotherapeutics, Inc. has on average historically risen by 110% based on the past 5 years of stock performance.

Arcutis Biotherapeutics, Inc. Stock Rating

Buy

Arcutis Biotherapeutics, Inc. (ARQT) is a Buy

Is Arcutis Biotherapeutics, Inc. overpriced?

Arcutis Biotherapeutics, Inc. has risen higher in 3 of those 5 years over the subsequent 52-week period, corresponding to a historical accuracy of 60%

Arcutis Biotherapeutics, Inc. Stock Price History

Is ARQT stock going to rise?

Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and ARQT is experiencing buying pressure, which is a positive indicator for future bullish movement.

Stock Information

Stock Info

Exchange:

NASDAQ

Country:

United States

Industry:

Biotechnology

Sector:

Health Care

Type:

stock

Website:

arcutis.com

52-Week Data

52-Week High:

31.27

52-Week Low:

11.13

Prediction Charts

Market Cap:

3.7B

Price in USD:

29.96

Volume:

1.8M

Beta:

1.19

Technical Analysis

SMA50:

23.42

SMA100:

19.63

SMA200:

16.94

52-Wk Change:

144.17%

Stock Predictions

Is Arcutis Biotherapeutics, Inc. stock public?

Yes, Arcutis Biotherapeutics, Inc. is a publicly traded company.
What is the Arcutis Biotherapeutics, Inc. stock quote today?

The Arcutis Biotherapeutics, Inc. stock price is 29.96 USD today.
How to buy Arcutis Biotherapeutics, Inc. stock online?

You can buy Arcutis Biotherapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date	Opening	Closing	Minimum	Maximum
Nov-13	23.37	22.86	23.77	22.78
Nov-14	22.28	25.00	25.20	22.26
Nov-17	24.86	26.17	26.82	24.82
Nov-18	25.87	27.28	27.92	25.55
Nov-19	27.21	27.89	28.96	27.00
Nov-20	28.40	27.33	28.49	27.22
Nov-21	27.15	29.49	30.01	27.08
Nov-24	29.84	30.76	31.10	29.64
Nov-25	30.75	30.73	31.00	30.25
Nov-26	30.98	30.96	31.11	30.38
Nov-28	31.27	30.65	31.27	30.39
Dec-1	30.24	30.37	30.65	29.85
Dec-2	30.14	29.43	30.48	28.95
Dec-3	29.76	29.96	30.18	29.28

Arcutis Biotherapeutics, Inc. Earnings

Arcutis Biotherapeutics, Inc. Earnings Report: Per Share Arcutis Biotherapeutics, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.

Arcutis Biotherapeutics, Inc. Forecast Revenue Growth

Arcutis Biotherapeutics, Inc. Stock Analysis: Historical quarterly revenues per share for Arcutis Biotherapeutics, Inc. and historical quarterly revenue growth:

Analysts estimate an earnings increase this quarter of $0.25 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.19 per share, and an increase next year of $0.60 per share.

* Arcutis Biotherapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.